Viral load-driven systemic immune exhaustion is an enabler of antibody breadth in HIV infection
Authors:
- Izumi de Los Rios KobaraIKIzumi de Los Rios Kobara
- Uma M MangalanathanUMUma M Mangalanathan
- Soneida Deline-CaballeroSDSoneida Deline-Caballero
- Kassandra PinedoKPKassandra Pinedo
- Camilo Espinosa BernalCBCamilo Espinosa Bernal
- Hannah L. ItellHIHannah L. Itell
- R. Scott McClellandRMR. Scott McClelland
- Kishorchandra MandaliyaKMKishorchandra Mandaliya
- Julie OverbaughJOJulie Overbaugh
- Catherine A. BlishCBCatherine A. Blish
Preprint
Abstract
A broadly neutralizing response to a human immunodeficiency virus (HIV) vaccine is a major goal of the field, yet the determinants of antibody breadth remain poorly defined. Antibody responses to HIV evolve over years of infection, developing unusual features such as high mutation rates in the subset of individuals that acquire breadth. Using single-cell RNA sequencing, single-cell proteomics, and plasma neutralization assays in a longitudinal Kenyan cohort of treatment-naive women living with HIV, we identify systems-level immune correlates of antibody breadth. Broad and narrow neutralizers diverge early in infection along a viral load-driven axis with broad neutralizers exhibiting greater viral loads and CD4 T cell decline; concurrently, NK cells, CD8 T cells, and monocytes, broad neutralizers displayed greater magnitude of immune activation in early infection, followed by exhaustion in late infection. This functional decline may dampen NK cell-mediated pruning of T follicular helper cells, creating a permissive environment for sustained germinal center activity and antibody maturation. Narrow neutralizers, by contrast, maintain functional cellular immunity but lack the antigenic pressure and permissive exhaustive state associated with breadth. Together, these findings suggest that antibody breadth in HIV infection reflects failed viral control rather than a successful antiviral response with implications for vaccination and cure strategies that must balance cellular and humoral immunity.Keywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1113682)
- National Institutes of Health (AI007290)
- National Institutes of Health (HD103571)
This publication has 149 references indexed in Scilit:
- Cytotoxic CD4 T Cells: Dual Agents in HIV-1 Pathogenesis and PersistenceCurrent HIV/AIDS Reports, 2026
- A perspective on LILRBs and LAIR1 as immune checkpoint targets for cancer treatmentBiochemical and Biophysical Research Communications, 2022
- Complex heatmap visualizationiMeta, 2022
- AP‐1 and NF‐κB synergize to transcriptionally activate latent HIV upon T‐cell receptor activationFEBS Letters, 2021
- LILRB receptor-mediated regulation of myeloid cell maturation and functionCancer Immunology, Immunotherapy, 2017
- Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic AntibodyCell, 2016
- Normalization of mass cytometry data with bead standardsCytometry Part A, 2013
- CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual‐tropic (R5/X4) HIV‐1 infectionEuropean Journal of Immunology, 2011
- Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptorsEuropean Journal of Immunology, 2000
- Dual role of TNF-α in NK / LAK cell-mediated lysis of chronically HIV-infected U1 cells. Concomitant enhancement of HIV expression and sensitization of cell-mediated lysisEuropean Journal of Immunology, 1999